Emerging Antitumor Activities of the Bitter Melon (Momordica charantia)
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Emerging Antitumor Activities of the Bitter Melon (Momordica charantia). / Fang, Evandro Fei; Froetscher, Lynn; Scheibye-Knudsen, Morten; Bohr, Vilhelm A; Wong, Jack Ho; Ng, Tzi Bun.
I: Current Protein and Peptide Science, Bind 20, Nr. 3, 2019, s. 296-301.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Emerging Antitumor Activities of the Bitter Melon (Momordica charantia)
AU - Fang, Evandro Fei
AU - Froetscher, Lynn
AU - Scheibye-Knudsen, Morten
AU - Bohr, Vilhelm A
AU - Wong, Jack Ho
AU - Ng, Tzi Bun
N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
PY - 2019
Y1 - 2019
N2 - Bitter melon or bitter gourd (Momordica charantia) is a common vegetable in Asia and it is distinctive for its bitter taste. As an ingredient in folk medicine, research from different laboratories in recent years supports its potential medicinal applications with anti-tumor, anti-diabetic, anti-HIV activities in both in vitro and animal studies. In this short review, we summarize herein the recent progress in the antitumor aspect of bitter melon with a focus on the underlying molecular mechanisms. Further mechanistic studies as well as clinical trials are necessary to further verify its medicinal applications.
AB - Bitter melon or bitter gourd (Momordica charantia) is a common vegetable in Asia and it is distinctive for its bitter taste. As an ingredient in folk medicine, research from different laboratories in recent years supports its potential medicinal applications with anti-tumor, anti-diabetic, anti-HIV activities in both in vitro and animal studies. In this short review, we summarize herein the recent progress in the antitumor aspect of bitter melon with a focus on the underlying molecular mechanisms. Further mechanistic studies as well as clinical trials are necessary to further verify its medicinal applications.
U2 - 10.2174/1389203719666180622095800
DO - 10.2174/1389203719666180622095800
M3 - Journal article
C2 - 29932035
VL - 20
SP - 296
EP - 301
JO - Current Protein and Peptide Science
JF - Current Protein and Peptide Science
SN - 1389-2037
IS - 3
ER -
ID: 213162792